EFFICACY AND SAFETY OF COTADUTIDE, A DUAL GLP1-GLUCAGON RECEPTOR AGONIST, IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND T2DM

被引：0
|
作者：
Selvarajah, Viknesh [1 ]
Robertson, Darren [1 ]
Hansen, Lars [2 ]
Jermutus, Lutz [1 ]
Smith, Kirsten [1 ]
Frickleton, Celeste [2 ]
Coggi, Angela [1 ]
Sanchez, Jose [3 ]
Chang, Yi-Ting [2 ]
Parker, Victoria [1 ]
机构：
[1] AstraZeneca, Res & Early Dev, Cardiovasc Renal & Metab, BioPharmaceut R&D, Cambridge, England
[2] AstraZeneca, Res & Early Dev, Cardiovasc Renal & Metab, BioPharmaceut R&D, Gaithersburg, MD USA
[3] AstraZeneca, Res & Early Dev, Cardiovasc Renal & Metab, BioPharmaceut R&D, Molndal, Sweden
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
3000
引用
收藏
页码：I87 / I87
页数：1
相关论文
共 50 条
  • [31] LY3437943 (LY), a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment
    Urva, Shweta
    Loh, Mei Teng
    Coskun, Tamer
    Du, Yu
    Benson, Charles
    Loghin, Corina
    Haupt, Axel
    Milicevic, Zvonko
    DIABETES, 2022, 71
  • [32] Polymorphisms in GLP-1 receptor gene and susceptibility to type 2 diabetes mellitus (T2DM)
    Nagase, T
    Ji, LN
    Leech, C
    Pezolesi, M
    Habener, J
    Krolewski, A
    DIABETES, 2003, 52 : A254 - A254
  • [33] Dual GLP-1 and glucagon receptor agonism with cotadutide significantly increases insulin secretion in overweight and obese adults with type 2 diabetes
    Golubic, R.
    Kennet, J.
    Parker, V.
    Robertson, D.
    Luo, D.
    Hansen, L.
    Jermutus, L.
    Ambery, P.
    Park, A.
    Evans, M.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 239 - 239
  • [34] Weekly GLP-1 Agonist Albiglutide Monotherapy Improves Glycemic Parameters in Japanese Type 2 Diabetes Mellitus (T2DM) Patients
    Nino, Antonio
    Okuda, Inaha
    Wilson, Timothy H.
    Yue, Lin
    Nakajima, Hiromu
    Tsuboi, Maho
    Carr, Molly C.
    DIABETES, 2016, 65 : A266 - A266
  • [35] Efficacy and Safety of Lixisenatide in Elderly T2DM Patients: Subanalysis from the GetGoal Program
    Hanefeld, Markolf
    Berria, Rachele
    Lin, Jay
    Aronson, Ronnie
    Darmon, Patrice
    Evans, Marc
    Van Gaal, Luc
    DIABETES, 2013, 62 : A232 - A233
  • [36] Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials
    Deng, Bixin
    Ruan, Tiechao
    Lu, Wenting
    Ying, Junjie
    Li, Shiping
    Zhou, Ruixi
    Mu, Dezhi
    ENDOCRINE, 2024, 86 (01) : 15 - 27
  • [37] Efficacy and Safety of PF-06291874 (PF), a Glucagon Receptor Antagonist Administered for 12 Weeks to Patients with Type 2 Diabetes Mellitus (T2DM) on Background Metformin Therapy
    Calle, Roberto A.
    Bergman, Arthur
    Somayaji, Veena
    Chidsey, Kristin
    Kazierad, David J.
    DIABETES, 2017, 66 : A327 - A327
  • [38] Efficacy and Safety of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist in Children With Chemotherapy-Induced Hyperglycemia
    Adly, Amira
    Ismail, Eman
    AlDagen, Manar
    Salah, Nouran
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S238 - S238
  • [39] Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: A prospective cohort study
    Kakegawa, Tatsuya
    Sugimoto, Katsutoshi
    Saito, Kazuhiro
    Yunaiyama, Daisuke
    Araki, Yoichi
    Wada, Takuya
    Takahashi, Hiroshi
    Yoshimasu, Yu
    Takeuchi, Hirohito
    Itoi, Takao
    MEDICINE, 2024, 103 (23)
  • [40] GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
    Neumiller, Joshua J.
    Alicic, Radica Z.
    Tuttle, Katherine R.
    KIDNEY AND DIALYSIS, 2022, 2 (03): : 386 - 398
12345